Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Feb;45(2):636-8.
doi: 10.1128/AAC.45.2.636-638.2001.

Mechanisms of macrolide resistance in clinical pneumococcal isolates in France

F Fitoussi  1 , C Doit, P Geslin, N Brahimi, E Bingen
Affiliations

Mechanisms of macrolide resistance in clinical pneumococcal isolates in France

F Fitoussi et al. Antimicrob Agents Chemother. 2001 Feb.

Abstract

The genetic basis of macrolide resistance was investigated in a collection of 48 genotypically unrelated clinical isolates of Streptococcus pneumoniae obtained between 1987 and 1997 in France. All strains were resistant to erythromycin, clindamycin, and streptogramin B, exhibiting a macrolide-lincosamide-streptogramin B resistance phenotype, and harbored the erm(B) gene. None of the strains carried the mef(A) or erm(A) subclass erm(TR) gene.

PubMed Disclaimer

References

    1. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption. J Chemother. 1999;11:35–43. - PubMed
    1. Baquero F, García-Rodríguez J A, García De Lomas J, Aguilar L The Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial resistance of 1, 113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996–1997) multicenter surveillance study. Antimicrob Agents Chemother. 1999;43:357–359. - PMC - PubMed
    1. Betriu C, Redondo M, Palau M L, Sánchez A, Gómez M, Culebras E, Boloix A, Picazo J J. Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci. Antimicrob Agents Chemother. 2000;44:1838–1841. - PMC - PubMed
    1. Bingen E, Fitoussi F, Doit C, Cohen R, Tanna A, George R, Loukil C, Brahimi N, le Thomas I, Deforche D. Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients. Antimicrob Agents Chemother. 2000;44:1453–1457. - PMC - PubMed
    1. Clancy J, Petitpas J, Dib-Hajj F, Yuan W, Cronan M, Kamath A V, Bergeron J, Retsema J A. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Mol Microbiol. 1996;22:867–879. - PubMed

MeSH terms